Ocular Therapeutix Inc. has announced inducement equity awards for its newly appointed Global Chief Commercial Officer, David W. Robinson. Effective January 21, 2026, Robinson received a non-statutory stock option to purchase up to 416,000 shares of Ocular’s common stock at an exercise price of $11.42 per share, with a ten-year term. The stock options vest over four years, with 25% vesting after one year and the remaining shares vesting in equal monthly installments over the subsequent three years. Additionally, Robinson was granted a restricted stock unit award for 136,000 shares, vesting in equal annual installments over three years, beginning January 21, 2027. Both awards are subject to continued service with the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on January 23, 2026, and is solely responsible for the information contained therein.